Eli Lilly and Company [s:lly] said late Thursday that the U.S. Food and Drug Administration has approved its drug Emgality for the preventive treatment of migraine in adults. Emgality is delivered via a once-a-month, self-administered, subcutaneous injection. Lilly said the drug, one of three in a new class of drugs recently approved for migraines, will be available to patients shortly after approval. Patients with commercial insurance will be candidates to receive Emgality for up to 12 months free as part of Lilly’s patient-support program, the company said. Lilly also said Emgality will be available for pickup at retail pharmacies. The drug maker said the efficacy and safety of Emgality was demonstrated in two Phase 3 clinical trials in patients with episodic migraine and one Phase 3 clinical trial in patients with chronic migraine.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.